Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $16.28, but opened at $14.49. Telix Pharmaceuticals shares last traded at $14.37, with a volume of 21,120 shares.
Wall Street Analysts Forecast Growth
TLX has been the subject of a number of recent research reports. HC Wainwright assumed coverage on shares of Telix Pharmaceuticals in a research report on Thursday, July 3rd. They set a "buy" rating and a $23.00 price objective for the company. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Finally, Wedbush restated an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th.
Read Our Latest Stock Analysis on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The firm has a 50 day simple moving average of $16.35 and a two-hundred day simple moving average of $16.95.
Hedge Funds Weigh In On Telix Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals during the first quarter valued at approximately $170,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth $297,000. Finally, ABC Arbitrage SA acquired a new position in Telix Pharmaceuticals during the first quarter worth about $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
